Strontium Ranelate: State of the Art

Strontium ranelate is a new antiosteoporotic treatment that has an original mechanism of action on bone turnover. Preclinical studies have shown that strontium ranelate decreases bone resorption and increases bone formation, resulting in an increase in bone mass. In Phase III studies in postmenopausal osteoporotic women, strontium ranelate (2 g/day) reduced the risk of vertebral fracture by 41% (p ≤ 0.001) and the risk of nonvertebral fracture by 16% (p = 0.04) over 3 years. Strontium ranelate safety was considered to be good. Strontium ranelate 2 g/day is a new and effective therapeutic option in postmenopausal osteoporosis.

[1]  C. Roux,et al.  Strontium ranelate: state of the art. , 2005, Women's health.

[2]  R. Rizzoli,et al.  Strontium Ranelate Improves Bone Resistance by Increasing Bone Mass and Improving Architecture in Intact Female Rats , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  L. Quarles,et al.  A Novel Cation‐Sensing Mechanism in Osteoblasts Is a Molecular Target for Strontium , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[5]  P. Marie,et al.  S12911-2 reduces bone loss induced by short-term immobilization in rats. , 2003, Bone.

[6]  E. Brown,et al.  Is the calcium receptor a molecular target for the actions of strontium on bone? , 2003, Osteoporosis International.

[7]  M. Dougados,et al.  Prevention of Early Postmenopausal Bone Loss by Strontium Ranelate: The Randomized, Two-Year, Double-Masked, Dose-Ranging, Placebo-Controlled PREVOS Trial , 2002, Osteoporosis International.

[8]  R. Baron,et al.  In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. , 2002, European journal of pharmacology.

[9]  P. Marie,et al.  Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. , 2002, Metabolism: clinical and experimental.

[10]  D O Slosman,et al.  Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. , 2002, The Journal of clinical endocrinology and metabolism.

[11]  P. Chappuis,et al.  Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). , 2001, Bone.

[12]  D. Slosman,et al.  Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. , 1999, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[13]  P. Meunier,et al.  Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  P. Marie,et al.  The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. , 1996, Bone.

[15]  P. Marie,et al.  An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen‐deficient rats , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.